Pasupathi Sundaramoorthy
Overview
Explore the profile of Pasupathi Sundaramoorthy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiang K, Wang E, Mantyh J, Rupprecht G, Negrete M, Sanati G, et al.
Adv Sci (Weinh)
. 2024 Feb;
11(16):e2303379.
PMID: 38380561
Patient-Derived Organoids (PDO) and Xenografts (PDX) are the current gold standards for patient-derived models of cancer (PDMC). Nevertheless, how patient tumor cells evolve in these models and the impact on...
2.
Kang Y, Sundaramoorthy P, Gasparetto C, Feinberg D, Fan S, Long G, et al.
Ann Hematol
. 2022 Dec;
102(2):369-383.
PMID: 36460794
Multiple myeloma (MM) remains an incurable disease and there is an unmet medical need for novel therapeutic drugs that do not share similar mechanisms of action with currently available agents....
3.
Jabbar S, Mathews P, Wang X, Sundaramoorthy P, Chu E, Piryani S, et al.
Exp Hematol Oncol
. 2022 Nov;
11(1):83.
PMID: 36316713
Background: Thioredoxin-1 (TXN1) is one of the major cellular antioxidants in mammals and is involved in a wide range of physiological cellular responses. However, little is known about the roles...
4.
Huang W, Liu Y, Luz A, Berrong M, Meyer J, Zou Y, et al.
Front Immunol
. 2021 Oct;
12:754083.
PMID: 34712241
Myeloid-derived suppressor cells (MDSCs) are a hetero geneous group of cells, which can suppress the immune response, promote tumor progression and impair the efficacy of immunotherapies. Consequently, the pharmacological targeting...
5.
Fan S, Price T, Huang W, Plue M, Warren J, Sundaramoorthy P, et al.
Adv Sci (Weinh)
. 2020 Mar;
7(5):1900860.
PMID: 32154065
The roles of mitochondrial dysfunction in carcinogenesis remain largely unknown. The effects of PTEN-induced putative kinase 1 (PINK1)-dependent mitophagy on the pathogenesis of multiple myeloma (MM) are determined. The levels...
6.
Vijayakumar A, Baskaran R, Baek J, Sundaramoorthy P, Yoo B
AAPS PharmSciTech
. 2019 Jan;
20(2):88.
PMID: 30675630
Our aim was to investigate the cellular uptake, in vitro cytotoxicity and bioavailability of ginsenoside-modified nanostructured lipid carrier loaded with curcumin (G-NLC). The formulation was prepared by melt emulsification technique,...
7.
Sundaramoorthy P, Gasparetto C, Kang Y
Cancer Med
. 2018 May;
7(7):3257-3268.
PMID: 29761903
Multiple myeloma (MM) remains an incurable disease in need of the development of novel therapeutic agents and drug combinations. ABT-199 is a specific Bcl-2 inhibitor in clinical trials for MM;...
8.
Sundaramoorthy P, Wang Q, Zheng Z, Jiao Y, Chen B, Doan P, et al.
Stem Cell Res Ther
. 2017 Nov;
8(1):263.
PMID: 29141658
Background: Radiation exposure poses a significant threat to public health. Hematopoietic injury is one of the major manifestations of acute radiation sickness. Protection and/or mitigation of hematopoietic stem cells (HSCs)...
9.
Ramasamy T, Sundaramoorthy P, Ruttala H, Choi Y, Shin W, Jeong J, et al.
Drug Deliv
. 2017 Sep;
24(1):1262-1272.
PMID: 28891336
Since breast cancer is one of the most lethal malignancies, targeted strategies are urgently needed. In this study, we report the enhanced therapeutic efficacy of docetaxel (DTX) when combined with...
10.
Park M, Sundaramoorthy P, Sim J, Jeong K, Kim H
Anticancer Res
. 2016 Dec;
37(1):103-114.
PMID: 28011480
Aim: To investigate the possibility of enhancing an anti-metastatic effect of 5-fluorouracil (5-FU) on colorectal cancer (CRC) cells by combining it with continuous calcium supplementation. Materials And Methods: Optimal doses...